Gilead Sciences GILD · NASDAQ
$156.04 -0.73% (-$1.15)
Summary
36 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 23% a year over the last 3 years.
- It has raised its dividend 10 years in a row.
- Out of every 100 USD of revenue, 43 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Repaying its net debt would take 36.3 years of operating profit.
- Revenue grew by only 2.6% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 3.6% a year over 5 years. Over the last 3 years it grew by 2.6% a year. For the next fiscal year analysts expect revenue to grow by 4.4%. Earnings per share grew by 23% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $3.24B.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.0 years of free cash flow. Its debt is larger than its cash. The debt score is low because of the debt-to-equity ratio (2.2x).
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.12%
- Raised in a row
- 10 years
You receive $3.25 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 39
- Hold 18
- Sell 1
Today's price within the analysts' price targets
The average target of $153.13 is 1.9% below today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Biktarvy 49%
- Descovy 9.4%
- Genvoya 5.1%
- Yescarta 5.1%
- Trodelvy 4.7%
- Other 27%
By region
- UNITED STATES 71%
- Europe 17%
- Other International 12%
Biktarvy brings in 49% of revenue. Trodelvy grew fastest, by 38% a year.
Segments in detail